{"disease":{"id":"advanced-malignant-solid-tumor","name":"advanced malignant solid tumor"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07480733","title":"Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":480,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT07287995","title":"A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":428,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT06115642","title":"A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":340,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT04225117","title":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":329,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT04585750","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"PMV Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT06464055","title":"A Study of GQ1010 in Subjects With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT07391644","title":"A Study of JSKN027 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT04145622","title":"Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT07292402","title":"JSKN022 in Subjects With Advanced Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT02721732","title":"Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":157,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT07459920","title":"Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":156,"lead_sponsor_name":"National Cancer Institute, Naples","has_results":false},{"nct_id":"NCT06154343","title":"A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT07293754","title":"An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Repertoire Immune Medicines","has_results":false},{"nct_id":"NCT06592417","title":"To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":140,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT05103358","title":"Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Aadi Bioscience, Inc.","has_results":false},{"nct_id":"NCT05396339","title":"A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors.","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"SUNHO（China）BioPharmaceutical CO., Ltd.","has_results":false},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05277454","title":"Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":113,"lead_sponsor_name":"Hutchison Medipharma Limited","has_results":false},{"nct_id":"NCT07368127","title":"A Study of TPD3310 in Patients With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":112,"lead_sponsor_name":"TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.","has_results":false},{"nct_id":"NCT07050641","title":"Phase I/II Study of SCTB39-1 in Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Sinocelltech Ltd.","has_results":false},{"nct_id":"NCT06717750","title":"A Study of CSCJC3456 in Patients With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":102,"lead_sponsor_name":"Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.","has_results":false},{"nct_id":"NCT04328506","title":"Bioequivalency Study of CM082 Tablet in Healthy Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"AnewPharma","has_results":false},{"nct_id":"NCT06571422","title":"Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":93,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT06380309","title":"A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFE","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":89,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT02159989","title":"Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05886374","title":"A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":81,"lead_sponsor_name":"Hutchmed","has_results":false},{"nct_id":"NCT06166472","title":"A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT04226066","title":"Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":69,"lead_sponsor_name":"Tasly Tianjin Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT01738139","title":"Ipilimumab and Imatinib Mesylate in Advanced Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07028047","title":"Evaluation of WGc-043 Injection in Advanced Solid Tumors: Phase I Study","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":64,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04165590","title":"Plasmodium Immunotherapy for Advanced Malignant Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"CAS Lamvac Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT03872427","title":"Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":54,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04908046","title":"A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Hutchmed","has_results":false},{"nct_id":"NCT05098405","title":"First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":46,"lead_sponsor_name":"Molecular Partners AG","has_results":false},{"nct_id":"NCT06573294","title":"Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Genmab","has_results":false},{"nct_id":"NCT06713148","title":"Study on the Safety and Efficacy of Intratumoral Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":42,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05773937","title":"A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Mabwell (Shanghai) Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT03171220","title":"Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT06718946","title":"Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":38,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06499350","title":"A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"FindCure Biosciences (ZhongShan) Co., Ltd.","has_results":false},{"nct_id":"NCT05477849","title":"A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Shanghai Virogin Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT06658951","title":"Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"UTC Therapeutics Inc.","has_results":false},{"nct_id":"NCT07077252","title":"Phase I/II Study of SCTB39G in Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Sinocelltech Ltd.","has_results":false},{"nct_id":"NCT03932565","title":"Interventional Therapy Sequential With the Fourth-generation CAR-T Targeting Nectin4/FAP for Malignant Solid Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"The Sixth Affiliated Hospital of Wenzhou Medical University","has_results":false},{"nct_id":"NCT04864379","title":"Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Sir Run Run Shaw Hospital","has_results":false},{"nct_id":"NCT03662815","title":"Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Sir Run Run Shaw Hospital","has_results":false},{"nct_id":"NCT02045095","title":"A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":29,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05326035","title":"A Study of WJ05129 in Advanced Malignant Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":26,"lead_sponsor_name":"Suzhou Junjing BioSciences Co., Ltd.","has_results":false},{"nct_id":"NCT07010523","title":"Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Zhejiang University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}